Fylde and Wyre CCG Medicines Optimisation

Click each header to expand its content

Fylde and Wyre medicines RAG list

Application forms

Medicines commissioning policies

Actipatch for pain management 0.6 MB276
Albiglutide for type-2 diabetes mellitus 0.3 MB198
Alprostadil Cream For ED 0.3 MB194
Azelastine Fluticasone (Dymista) Nasal Spray 0.1 MB309
Bazedoxifene for oestrogen deficiency symptoms 0.3 MB187
Botulinum Toxin A for Spasticity and Contracture of the joint 0.3 MB203
Brimonidine For Erythema Of Rosacea 0.1 MB173
Brivaracetam for epilepsy 0.3 MB185
Budesonide multimatrix MMX 9mg prolonged release tablets 0.2 MB264
Certolizumab For Psoriatic Arthritis 0.1 MB154
Co-Proxamol For pain management 0.3 MB339
Co-trimoxazole for the prophylaxis of pneumocystis jirovecii (pneumocystis carinii) infections 0.3 MB190
Co-trimoxazole Prophylaxis of Primary and Secondary Spontaneous Bacterial Peritonitis (SBP) 0.1 MB214
Colesevelam (Cholestagel® ) For combination or monotherapy for familial hypercholesterolaemia 0.3 MB169
Colistimethate sodium/Colistin sulfomethate sodium (Colomycin® ) For non-Cystic Fibrosis in Patients with Bronchiectasis Colonised with Pseudomonas Aeruginosa 0.2 MB153
Conditions for which over the counter items should not routinely be prescribed in primary care 0.9 MB345
Daily selective serotonin re-uptake inhibitors (SSRIs) for the treatment of premature ejaculation (PE) 0.2 MB135
Dapoxetine for the treatment of premature ejaculation (PE) 0.2 MB148
Denosumab for GIO 0.2 MB127
Dulaglutide for the treatment of Type II Diabetes Mellitus in adults 0.3 MB199
Eflornithine-cream-for-facial-hirsutism 0.2 MB187
Eltrombopag For Thrombocytopenia In Hepatitis C 0.1 MB129
Eslicarbazepine For Focal Seizures 0.1 MB171
Evolocumab (Repatha SureClick® ) For prevention of cardiac events in patients with CHD and a history of ACS, in combination with a statin 0.1 MB161
Ferric Maltol 30mg Capsules in Adults for the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease 0.3 MB159
Fluorouracil-5-cream-for-basal-cell-carcinomas 0.1 MB148
Gluten-Free-Food-Products 0.3 MB181
Guanfacine-for-ADHD 0.3 MB148
Imiquimod-5-cream-for-basal-cell-carcinomas 0.2 MB145
Insulin Degludec And Liraglutide 0.2 MB155
Insulin-Aspart-for-Diabetes-Mellitus 0.3 MB175
Insulin-Degludec-for-DM 0.3 MB164
Insulin-Detemir-for-DM 0.2 MB128
Insuline-Glargine-for-T1DM 0.3 MB144
Insuline-Glargine-for-T2DM 0.3 MB146
Invicorp-injection-for-erectile-dysfunction 0.3 MB234
Ivermectin-cream-for-rosacea 0.3 MB158
JIA Policy For Adults (Version 1.0) 0.2 MB142
Lamotrigine-for-trigeminal-neuralgia 0.3 MB156
Lamotrigine-for-trigeminal-neuralgia 2 0.3 MB166
Levonorgestrel 13.5mg IUD 0.3 MB137
Lidocaine Plasters For PHN 0.2 MB148
Lidocaine-plasters-for-unlicensed-indications 0.3 MB232
Liothyronine-for-refractory-hypothyroidism 0.2 MB199
Liraglutide-for-obesity 0.3 MB164
Lisdexamfetamine-for-ADHD-in-adults 0.3 MB214
Lisdexamfetamine-for-ADHD-update 0.3 MB157
Lurasidone-for-Schizophrenia 0.3 MB186
Magnaspartate For Hypomagnesaemia 0.3 MB556
Metformin-for-reductionof-risk-or-delay-type-2-daibetes 0.2 MB139
Metformin-for-reductionof-risk-or-delay-type-2-daibetes 2 0.2 MB123
Midazolam-Epistatus-for-seizures 0.2 MB230
Opicapone-for-Parkinsons-disease-v2 0.5 MB178
Ospemifene for VVA 0.2 MB268
Oxycodone-Naloxone-for-Restless-legs 0.3 MB141
Paravit-CF-for-dietary-management-of-patients-with-cystic-fibrosis 0.2 MB719
Patiromer-for-hyperkalaemia 0.3 MB158
Patiromer-for-hyperkalaemia 2 0.3 MB177
Phosphodiesterase Type-5 Inhibitors 0.2 MB147
Pitolisant-for-Narcolepsyv2 0.3 MB179
Policy On Brand Inhaler Prescribing 0.3 MB285
Probiotics And VSL 0.3 MB163
Relvar Ellipta for COPD and asthma in adults 63 KB140
Rituximab-for-AIHA 0.4 MB174
Rituximab-for-ITP 0.4 MB151
Rivaroxaban-10mg-for-DVT-and-PE-and-extended-use 0.1 MB155
Safinamide-for-Parkinsons-disease 0.3 MB175
Second Line Anti-TNF For PsA 0.2 MB159
Second-generation-LA-antipsychotics 0.3 MB181
Secukinumab-for-Palmoplantar-psoriasis 0.3 MB144
Secukinumab-for-Palmoplantar-psoriasis 2 0.3 MB133
Semaglutide for type 2 DM 0.2 MB134
Silk Garments For Eczema And Dermatitis 0.2 MB144
Simbrinza for chronic open angle glaucoma 0.1 MB135
Sodium Oxybate for Narcolepsy with Cataplexy 0.3 MB179
Spironolactone For Acne 0.1 MB194
Subcutaneous Depot Medroxyprogesterone Acetate 0.1 MB149
Tadalafil daily 0.3 MB253
Tapentadol for neuropathic pain in non-palliative care 0.4 MB164
Tapentadol for non-specific pain 0.2 MB157
Testosterone For Female Sexual Dysfunction 0.1 MB139
Tiotropium For Asthma 0.2 MB135
Tocilizumab SC For RA 0.1 MB121
Trelegy inhaler for COPD 0.3 MB240
Trimbow inhaler for COPD 0.4 MB189
Trimbow-inhaler-for-COPD 0.4 MB6
Ulipristal acetate for uterine fibroids 0.5 MB152
Umeclidinium For COPD 0.2 MB135
Vedolizumab For Crohn's Disease 0.2 MB110
Vesomni For Benign Prostatic Hyperplasia 0.1 MB127
Vitamins (inc Renavit) For Dialysis 0.3 MB251
Waterproof Cast Cover Policy 0.1 MB388
Xonvea for nausea and vomiting in pregnancy 0.1 MB129

Medicines guidelines, information sheets, and shared care

Further medicines guidelines are available on Lancashire Medicines Management Group’s website.

Algorithm-for-antihyperglycaemic-therapy-in-adults-with-type-II-v1.5[3] 0.5 MB92
Asthma treatment guideline for children 0.4 MB70
Azathioprine-Mercaptopurine-SCG-Version 0.2 MB311
BGTS and Meters Guideline Nov16 1.2 MB1166
Cannabis-based-medicinal-products-for-pain-POSITION-STATEMENT-version-1.1[1] 0.3 MB100
Ciclosporin-SCG-Version 0.2 MB180
Commissioining Policy For Nutritional Supp Post Bariatirc Surgery Apr13 83 KB193
Conditions-for-which-OTC-items-should-not-routinely-be-prescribed-in-pri .. 0.9 MB251
Dalteparin SCG 2018 0.2 MB194
Electronic-Repeat-Dispensing-guideline 1.7 MB1359
Emollient-Guideline-May-2017 0.2 MB1440
Flash Glucose Monitoring policy - L&SC 0.2 MB161
Flowchart-for-Vitamin-D-Deficiency-in-Primary-Care 0.3 MB463
Guidance to support the implementation of the valproate PREVENT programme 0.5 MB274
Guidance-for-7-day-prescriptions-FWCCG-Apr2018 0.5 MB315
Lancashire and South Cumbria Self-Care and Acces to OTC Medicines – Temp... 83 KB65
Leflunomide-SCG-Version 0.2 MB185
LSCMMG OTC Items that Should not be Routinely Prescribed in Primary Care... 0.2 MB101
MDS Briefing Doc Oct 13 43 KB151
Methotrexate-SCG-Version 0.2 MB331
Mgt-of-Infection-Primary-Care-Guidance-January-2017-version2 0.7 MB820
Patient information - Emollients.steroid.barrier creams 0.2 MB139
Patient information - Emollients.steroid.barrier creams 0.2 MB362
Patient information - spacer devices 0.2 MB176
Patient information - spacer devices 0.2 MB176
Penicillamine-SCG-Version 0.2 MB168
Policy Unlicensed Herbal Vits Mins Supplements 2013 77 KB124
Position Statement OPIOID PRESCRIBING max dose Final Version 1.1 0.1 MB96
Prescribing-Nutritional-Supplements-Post-Bariatric-Surgery-Version-1.2[1] 0.3 MB80
Prescribing-Nutritional-Supplements-Post-Bariatric-Surgery-Version-1.2[1] 0.3 MB77
RMOC-Liothyronine-Guidance-v2.0-final-1 0.5 MB137
Sodium-Aurothiomalate-SCG-Version 0.2 MB12
Sulfasalazine 0.2 MB244
Testosterone-Shared-Care-Guideline-Version-1.2[1] 0.3 MB87
Wound Care Formulary 8.2 MB800

Primary care rebate schemes

Primary care rebate schemes are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.

Current Primary Care Rebate Schemes in place:

  • Clenil Modulite (Beclometasone) – Started July 2019
  • Fencino (Fentanyl) – Started April 2016
  • Firmagon (Degarelix) – Started September 2016
  • Januvia (Sitagliptin) – Started September 2018
  • Lixiana (Edoxaban) – Started February 2018
  • Longtec (Oxycodone SR) – Started July 2019
  • Sereflo (Fluticasone / Salmeterol) – Started July 2019
  • Seretide (Fluticasone / Salmeterol) – Started April 2016
  • Xarelto (Rivaroxaban) – Started October 2019
  • Zoladex (Goserelin) – Started January 2019

Fact and advice sheets

Inhaler Techniques

Inhaler technique videos are available to view online.

Last updated on 18 December 2019 at 11:14 by Senior communications and engagement officer N